Rational Drug Design
Overview
Authors
Affiliations
In this article, current knowledge of drug design is reviewed and an approach of rational drug design is presented. The process of drug development is challenging, expensive, and time consuming, although this process has been accelerated due to the development of computational tools and methodologies. The current target based drug design approach is incomplete because most of the drugs developed by structure guided approaches have been shown to have serious toxic side effects. Otherwise these drugs would have been an ideal choice for the treatment of diseases. Hence, rational drug design would require a multidisciplinary approach. In this regard, incorporation of gene expression technology and bioinformatics tools would be indispensable in the structure based drug design. Global gene expression data and analysis of such data using bioinformatics tools will have numerous benefits such as efficiency, cost effectiveness, time saving, and will provide strategies for combination therapy in addition to overcoming toxic side effects. As a result of incorporation of gene expression data, partial benefit of the structure based drug design is slowly emerging and rapidly changing the approach of the drug development process. To achieve the full benefit of developing a successful drug, multidisciplinary approaches (approaches such as computational chemistry and gene expression analysis, as discussed in this article) would be necessary. In the future, there is adequate room for the development of more sophisticated methodologies.
Text-guided small molecule generation via diffusion model.
Luo Y, Fang J, Li S, Liu Z, Wu J, Zhang A iScience. 2025; 27(11):110992.
PMID: 39759073 PMC: 11700631. DOI: 10.1016/j.isci.2024.110992.
A survey of generative AI for de novo drug design: new frontiers in molecule and protein generation.
Tang X, Dai H, Knight E, Wu F, Li Y, Li T Brief Bioinform. 2024; 25(4).
PMID: 39007594 PMC: 11247410. DOI: 10.1093/bib/bbae338.
Structure-activity relationship of pharmacophores and toxicophores: the need for clinical strategy.
Saganuwan S Daru. 2024; 32(2):781-800.
PMID: 38935265 PMC: 11555194. DOI: 10.1007/s40199-024-00525-y.
Fonseca-Benitez V, Acosta-Guzman P, Sanchez J, Alarcon Z, Jimenez R, Guevara-Pulido J Molecules. 2024; 29(8).
PMID: 38675620 PMC: 11052204. DOI: 10.3390/molecules29081802.
The small molecule CBR-5884 inhibits the phosphatidylserine synthase.
Zhou Y, Phelps G, Mangrum M, McLeish J, Phillips E, Lou J mBio. 2024; 15(5):e0063324.
PMID: 38587428 PMC: 11077991. DOI: 10.1128/mbio.00633-24.